Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial (TD-NeoFOUR trial)

MLA

Hongtao Duan, et al. “Perioperative Sintilimab and Neoadjuvant Anlotinib plus Chemotherapy for Resectable Non-Small-Cell Lung Cancer: A Multicentre, Open-Label, Single-Arm, Phase 2 Trial (TD-NeoFOUR Trial).” Signal Transduction and Targeted Therapy, vol. 9, no. 1, Oct. 2024, pp. 1–9. EBSCOhost, https://doi.org/10.1038/s41392-024-01992-0.

APA

Hongtao Duan, Changjian Shao, Zhilin Luo, Tianhu Wang, Liping Tong, Honggang Liu, Xin Yao, Jie Lei, Jinbo Zhao, Yuan Gao, Tao Jiang, & Xiaolong Yan. (2024). Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial (TD-NeoFOUR trial). Signal Transduction and Targeted Therapy, 9(1), 1–9. https://doi.org/10.1038/s41392-024-01992-0

Chicago

Hongtao Duan, Changjian Shao, Zhilin Luo, Tianhu Wang, Liping Tong, Honggang Liu, Xin Yao, et al. 2024. “Perioperative Sintilimab and Neoadjuvant Anlotinib plus Chemotherapy for Resectable Non-Small-Cell Lung Cancer: A Multicentre, Open-Label, Single-Arm, Phase 2 Trial (TD-NeoFOUR Trial).” Signal Transduction and Targeted Therapy 9 (1): 1–9. doi:10.1038/s41392-024-01992-0.